The present invention relates to a pharmaceutical combination for the treatment of renal failure in pets, caused by various diseases or ineffective to traditional renal therapy or renal replacement therapy thereby incapable of restoring health. The pharmaceutical combination of the present invention is administered by subcutaneous injection to pets in need thereof, with various advantages including simple use, no requirement for surgery, hospitalization and/or fluid infusion, faster recovery of health status, reduced medical costs, significantly improved recovery rate, reduced mortality and the likes. The pharmaceutical combination of the present invention can also be used for the continuous care treatment of pets with renal failure.